Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK4 | Q9HAZ1 | 16/20 | 0.65 |
| ▸ | CLK2 | P49760 | 15/20 | 0.65 |
| ▸ | DYRK1A | Q13627 | 14/20 | 0.65 |
| ▸ | DYRK1B | Q9Y463 | 14/20 | 0.65 |
| ▸ | DYRK2 | Q92630 | 13/20 | 0.65 |
| ▸ | CLK3 | P49761 | 11/20 | 0.65 |
| ▸ | GSK3B | P49841 | 7/20 | 0.65 |
| ▸ | CLK1 | P49759 | 15/20 | 0.51 |
| ▸ | DYRK3 | O43781 | 13/20 | 0.51 |
| ▸ | DYRK4 | Q9NR20 | 8/20 | 0.51 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.51 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.45 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23970345 | 0.89 | CLK4 (0.60) | CLK4CLK2DYRK1ADYRK1BDYRK2 | |
| SCHEMBL23970534 | 0.85 | CLK1 (0.65) | CLK4CLK2DYRK1ADYRK1BDYRK2 | |
| SCHEMBL30144849 | 0.85 | CLK1 (0.64) | CLK4CLK2DYRK1ADYRK1BDYRK2 | |
| SCHEMBL28953216 | 0.85 | CLK1 (0.64) | CLK4CLK2DYRK1ADYRK1BDYRK2 | |
| SCHEMBL23510717 | 0.85 | CLK1 (0.64) | CLK4CLK2DYRK1ADYRK1BDYRK2 | |
| SCHEMBL23970067 | 0.83 | CLK1 (0.61) | CLK4CLK2DYRK1ADYRK1BDYRK2 | |
| SCHEMBL23970181 | 0.83 | CLK1 (0.61) | CLK4CLK2DYRK1ADYRK1BDYRK2 | |
| SCHEMBL31712172 | 0.82 | CLK1 (0.60) | CLK4CLK2DYRK1ADYRK1BDYRK2 | |
| SCHEMBL23970090 | 0.81 | CLK1 (0.62) | CLK4CLK2DYRK1ADYRK1BDYRK2 | |
| SCHEMBL23970299 | 0.80 | CLK4 (0.53) | CLK4CLK2DYRK1ADYRK1BDYRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4143185-A1 | NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | Perha Pharmaceuticals (FR) | 2023-03-08 | — | — | EP | claimed |
| CN-115515953-A | Novel imidazolidinone derivatives as inhibitors of protein kinases, in particular DYRK1A, CLK1 and/or CLK4 | 珀哈制药公司 | 2022-12-23 | — | — | CN | claimed |
| US-20230167104-A1 | NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | PERHA PHARMACEUTICALS (FR) | 2023-06-01 | — | — | US | disclosed |
| US-20230167104-A1 | NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | PERHA PHARMACEUTICALS (FR) | 2023-06-01 | — | — | US | disclosed |
| CN-115515953-A | Novel imidazolidinone derivatives as inhibitors of protein kinases, in particular DYRK1A, CLK1 and/or CLK4 | 珀哈制药公司 | 2022-12-23 | — | — | CN | disclosed |
| EP-3904354-A1 | NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | Perha Pharmaceuticals (FR) | 2021-11-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167104-A1 | NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | CLK1, CLK2, CLK3 | CLK4 4/4885CLK2 2/4885DYRK1A 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.